TB-500 + SS-31 + Humanin Cardiac Protection Stack

TB-500 (Thymosin Beta-4): Loading phase of 5-10 mg subcutaneously twice weekly for the first 4 weeks, then maintenance at 2-5 mg twice weekly. TB-500 promotes angiogenesis, reduces fibrosis, and supports cardiac tissue repair. The loading phase establishes tissue saturation before stepping down to maintenance. Inject subcutaneously in the abdominal area; rotation of injection sites is recommended.

SS-31 (Elamipretide): 10-40 mg subcutaneously once daily. SS-31 targets the inner mitochondrial membrane by binding cardiolipin, stabilizing electron transport chain complexes, and reducing reactive oxygen species production. This is particularly relevant for cardiac tissue, which has the highest mitochondrial density of any organ. Start at 10 mg and titrate based on tolerance. SS-31 is best administered in the morning.

Humanin: 1-3 mg subcutaneously daily. Humanin is a mitochondrial-derived peptide (MDP) encoded in mitochondrial DNA that activates cytoprotective pathways through STAT3 signaling, reduces endoplasmic reticulum stress, and has documented cardioprotective effects in ischemia-reperfusion models. It also improves endothelial function and reduces oxidative stress in vascular tissue. Start at 1 mg and increase to 3 mg over the first two weeks.

Cycle structure: 8-12 week cycles with 4 weeks off. TB-500 provides the tissue repair component, SS-31 optimizes mitochondrial energy production in cardiac cells, and humanin adds cytoprotective signaling. All three operate through distinct and complementary mechanisms. During the off-cycle, the structural benefits from TB-500 (new blood vessel formation, reduced fibrosis) and mitochondrial improvements from SS-31 persist. Cardiac biomarkers (BNP/NT-proBNP, troponin, hsCRP) should be monitored at baseline, 4 weeks, and end of cycle.